Key result
Benfluorex therapy (150 mg/day) was associated with the development of simultaneous mitral bioprosthesis hypertrophic scarring and native aortic valve fibrosis in a 40-year-old woman.
Case Report (n=1)
Benfluorex therapy may be associated with drug-induced heart disease, including bioprosthesis scarring and native valve fibrosis.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible benfluorex-related bioprosthetic complications; leaves causal confirmation and surveillance needs open.
The authors describe the case of a simultaneous mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy in a 40-year-old woman. Four years before, she underwent a mitral valve replacement after the diagnosis of mitral regurgitation during benfluorex treatment (150 mg/day). This drug was reintroduced postoperatively. She presented with exercise and sometimes resting dyspnoea. The bioprosthesis and aortic valves exhibited similar histopathological lesions. Thickening and plaque deposits made by smooth muscle alpha actin- and vimentin-positive cells in a glycosaminoglycan matrix were observed. The study discusses the putative contribution of circulating progenitor cells activated by 5-HT(2B) receptor agonists in the development of drug-induced heart disease.
No takes yet. Share an insight, caveat, or question.
Ayme‐Dietrich et al. (2012) conducted a case report in Mitral bioprosthesis hypertrophic scarring and native aortic valve fibrosis (n=1). Benfluorex was evaluated on Mitral bioprosthesis hypertrophic scarring and native aortic valve fibrosis. Benfluorex therapy (150 mg/day) was associated with the development of simultaneous mitral bioprosthesis hypertrophic scarring and native aortic valve fibrosis in a 40-year-old woman.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: